Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Listen on:
Episodes
Saturday Jun 14, 2025
Saturday Jun 14, 2025
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Cathy Eng, a renowned GI medical oncologist from the Vanderbilt Ingram Cancer Center, to discuss the most impactful updates from the ASCO 2025 annual meeting, specifically focusing on gastrointestinal (GI) malignancies.
Join us as we dive into five pivotal abstracts that are set to change the landscape of GI cancer treatment:
1. DYNAMIC III: Discover how ctDNA-guided adjuvant chemotherapy in stage 3 colon cancer did not improve outcomes, highlighting questionable role of escalating approach with ctDNA positivity.2. ATOMIC: Learn about the addition of atezolizumab to FOLFIRI in MSI-H disease stage 3 colon cancer, which improved disease-free survival with a hazard ratio of 0.50.3. BREAKWATER: Explore how the combination of encorafenib, cetuximab, and FOLFOX has established a new standard of care for BRAF V600E mutant metastatic colorectal cancer, doubling overall survival from 15 months to 30.3 months.4. MATTERHORN: Understand the use of durvalumab in the perioperative and postoperative setting with the FLOT regimen for resectable gastric and GE junction adenocarcinoma, showing significant improvements in event-free survival.5. DESTINY Gastric04: Delved into the findings that confirm TDXd as a preferred option in the second line and beyond for HER2 positive metastatic gastric cancer or GE junction adenocarcinoma.
YouTube: https://youtu.be/hllyI5S2Dqg
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Tune in for an insightful discussion that will keep you updated on the latest advancements in GI oncology! Don’t forget to subscribe for more episodes on treatment algorithms, FDA approvals, and conference highlights.
Saturday Jun 07, 2025
Saturday Jun 07, 2025
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu from Georgetown Lombardi Comprehensive Cancer Center to discuss the latest and most impactful findings from the ASCO 2025 meeting, focusing on lung cancer.
Join us as we dive into five key studies that could change clinical practice:
1. CheckMate 816: Discover the significant overall survival benefits of neoadjuvant chemotherapy combined with nivolumab in resectable non-small cell lung cancer.2. Timing of Immunotherapy: Explore a groundbreaking study that reveals how the timing of immunotherapy infusions can dramatically affect patient outcomes.3. NeoADAURA Trial: Learn about the use of osimertinib in the neoadjuvant setting for EGFR-mutated lung cancer and how it compares to established adjuvant therapies.4. IMforte Study: Understand the implications of maintenance therapy in small cell lung cancer and how it can improve overall survival rates.5. DeLLphi 304: Get insights into the efficacy of tarlatamab as a second-line treatment for small cell lung cancer and its potential to become the new standard of care.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Tune in for an engaging discussion filled with expert insights, clinical pearls, and the latest advancements in lung cancer treatment. Don't forget to like, subscribe, and check out our other conference highlights!#OncologyBrothers #LungCancer #ASCO2025 #CancerResearch #Immunotherapy #EGFR #SmallCellLungCancer #NeoadjuvantTherapy #Podcast
Monday May 26, 2025
Monday May 26, 2025
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study.
Join us as we delve into:• The significance of MSI-high status in colorectal cancer and its prevalence.• The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates.• The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy.• Important side effects associated with the combination therapy and how to manage them.• Insights on patient selection for immunotherapy, including considerations for age and comorbidities.• The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment.
YouTube: https://youtu.be/wJRlECiY2VA
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025!#OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW
Wednesday May 21, 2025
Wednesday May 21, 2025
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations.
In this informative discussion, they covered:• The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib.• Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions.• Strategies for managing these side effects to improve patient quality of life and treatment adherence.• Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches.
Youtube: https://youtu.be/v6fb6nx0YY4
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!
Monday May 19, 2025
Monday May 19, 2025
Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for small-cell lung cancer. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Ticiana Leal, a thoracic medical oncologist from the Winship Cancer Institute - Emory University.
In this episode, we covered:• Current treatment paradigm of small cell lung cancer, in localized setting and extensive stage.
• We covered the recent approval of durvalumab in limited stage setting post chemoRT.
• We touched on the role of growth factors, and how they get rarely utilized, and covered use of Trilaciclib.
• Stressed the importance of immunotherapy in extensive stage with choices of Atezolizumab and Durvalumab, and touched on extended survival data with Atezolizumab
• Talked about logistical issues and uptake of Tarlatamab post approval.• Stressed the importance of clinical trials to move the field ahead.
Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Thursday May 15, 2025
Thursday May 15, 2025
Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital.
In this episode, we covered:• Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations.• The importance of comprehensive NGS testing and the need for retesting at progression.• Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities.• Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies.• The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions.
Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.
YouTube: https://youtu.be/LMYDAjZcn5w
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Monday May 12, 2025
Monday May 12, 2025
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings.
Episode Highlights:• The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making.• Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy.• Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy.• Discussed KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies.• Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies.
Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals!
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Thursday May 08, 2025
Thursday May 08, 2025
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab.
The discussion covered:• Overview of the treatment landscape for biliary tract cancer• Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue• Management strategies for adverse events, including dose reductions and supportive care• Insights on Zanidatamab, its side effects, and infusion-related reactions• The importance of biomarker testing and patient-centered care in treatment decisions
Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Monday May 05, 2025
Monday May 05, 2025
Welcome to another episode of the Oncology Brothers podcast! In this episode, we dived into the recent FDA approval of Durvalumab combined with chemotherapy for resectable muscle-invasive bladder cancer, based on the NIAGARA trial.
Join us as we chat with Dr. Thomas Powles, a GU medical oncologist and the lead author of the NIAGARA trial. We discussed the study design, the significant improvements in overall survival, and the implications of this new treatment approach. Dr. Powles shared insights on the use of immunotherapy in the perioperative setting, the importance of pathological complete response, and the safety of combining Durvalumab with chemotherapy.
Key topics covered in this episode:• Overview of the NIAGARA trial and its findings• Comparison of Durvalumab and cisplatin-based chemotherapy outcomes• The significance of event-free survival and overall survival rates• Insights on managing side effects and treatment sequencing• The evolving role of ctDNA in determining treatment strategies
YouTube: https://youtu.be/s_tXoX5yhV8
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Tune in to learn how these advancements are changing the landscape of bladder cancer treatment and improving patient outcomes. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology and FDA approvals!#OncologyBrothers #BladderCancer #Dervalumab #FDAApproval #NiagaraTrial #Immunotherapy #CancerResearch #OncologyPodcast
Thursday May 01, 2025
Thursday May 01, 2025
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain, both practicing community medical oncologists, continue their discussion on HER2-positive biliary tract cancer. They are joined by Dr. Shubham Pant from MD Anderson, who shares his expertise on this rapidly evolving field.
In this episode, we cover:• The importance of HER2 testing in biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinomas and gallbladder cancers.• Who should be tested for HER2 positivity and how to classify HER2-positive disease.• The role of next-generation sequencing (NGS) and immunohistochemistry (IHC) in determining HER2 status.• Current treatment options for HER2-positive biliary tract cancer, including the latest clinical trials and approved therapies like trastuzumab deruxtecan and zanidatamab.• The significance of patient-centered decision-making and managing side effects associated with these treatments.• Insights into the potential for brain metastases in biliary tract cancer and the importance of ongoing surveillance.
Join us as we delve into the latest data and strategies for managing HER2-positive biliary tract cancer, and stay tuned for our next episode where we will discuss side effects and management of these therapies.
Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:https://www.gotoper.com/courses/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatment
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!